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Abstract 
Rationale: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that present 
variable outcomes. To date, no effective therapies or reliable prognostic markers are available for patients who 
develop metastatic PPGL (mPPGL). Our aim was to discover robust prognostic markers validated through in 
vitro models, and define specific therapeutic options according to tumor genomic features.  
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Methods: We analyzed three PPGL miRNome datasets (n=443), validated candidate markers and assessed 
them in serum samples (n=36) to find a metastatic miRNA signature. An integrative study of miRNome, 
transcriptome and proteome was performed to find miRNA targets, which were further characterized in vitro.  
Results: A signature of six miRNAs (miR-21-3p, miR-183-5p, miR-182-5p, miR-96-5p, miR-551b-3p, and 
miR-202-5p) was associated with metastatic risk and time to progression. A higher expression of five of these 
miRNAs was also detected in PPGL patients’ liquid biopsies compared with controls. The combined expression 
of miR-21-3p/miR-183-5p showed the best power to predict metastasis (AUC=0.804, P=4.67·10-18), and was 
found associated in vitro with pro-metastatic features, such as neuroendocrine-mesenchymal transition 
phenotype, and increased cell migration rate. A pan-cancer multi-omic integrative study correlated miR-21-3p 
levels with TSC2 expression, mTOR pathway activation, and a predictive signature for mTOR 
inhibitor-sensitivity in PPGLs and other cancers. Likewise, we demonstrated in vitro a TSC2 repression and an 
enhanced rapamycin sensitivity upon miR-21-3p expression. 
Conclusions: Our findings support the assessment of miR-21-3p/miR-183-5p, in tumors and liquid biopsies, as 
biomarkers for risk stratification to improve the PPGL patients’ management. We propose miR-21-3p to select 
mPPGL patients who may benefit from mTOR inhibitors. 
Key words: multi-omic integration; pheochromocytoma/paraganglioma; miR-21-3p; liquid biopsy; prognostic 
biomarker 
Introduction 
Pheochromocytomas and paragangliomas 
(PPGLs) are rare neuroendocrine tumors (3–8 cases 
per 106 person-year) with marked genetic 
heterogeneity [1]. Approximately 15-20% of patients 
with PPGLs develop metastases, and the 5-year 
overall survival rate after diagnosis of the first 
metastasis is 60% [2, 3]. Altough clinical 
characteristics such as tumor size, extra-adrenal 
location and increased plasma concentration of 
3-methoxytyramine could provide useful information 
to estimate the likelihood of metastasis [4–6], there are 
no histological criteria or clinically validated 
molecular biomarkers to identify patients whose 
tumors will become metastatic. Currently, SDHB 
mutation status is the only genetic factor associated 
with poor prognosis [7]. We recently reported that 
assessment of telomerase activation and ATRX 
mutations in tumor tissue may have clinical 
significance for identifying metastatic disease 
(mPPGLs) [8]. Nevertheless, most mPPGLs are 
currently diagnosed at advanced stages, thus 
precluding successful management of the disease [9]. 
Furthermore, no effective therapies are available for 
patients who develop mPPGL [10]. 
High-throughput omic platforms are robust 
technologies for identifying molecular mechanisms of 
tumorigenesis and potential markers for diagnosis, 
prognosis and response to treatment. In PPGLs, 
genomic profiling has led to the identification of 
several markers related to clinical variables, including 
mPPGL [11–13]. 
miRNAs regulate gene expression at the 
post-transcriptional level by targeting mRNAs for 
degradation and/or repressing their translation. 
Altered expression of miRNAs has been shown to be 
paramount for cancer-related processes, becoming a 
new class of cancer biomarkers detectable in tumor 
tissues and circulation. In PPGLs patients, some 
miRNAs have been associated with genotype or 
mPPGL [12, 14–21]. However, most series studied so 
far were small with limited follow-up, and lacked 
validation, which hinders the identification of 
miRNAs with prognostic value.  
Here, we perform a comprehensive analysis of 
miRNomes from 443 PPGLs with clinical and genetic 
information, aimed at identifying miRNAs predictive 
for mPPGL. We provide evidence of a metastatic 
signature, assessed in tumors and liquid biopsies, 
with prognostic value. Furthermore, integrative 
miRNA-mRNA analysis, TCGA proteomics and in 
vitro assays support a new role of miR-21-3p in mTOR 
pathway regulation, with potential therapeutic 
implications for mPPGL (Figure S1). 
Methods 
miRNA discovery 
Discovery of differentially expressed miRNAs. Three 
different public datasets [12, 16, 17] were used for 
extracting miRNA expression data from 443 samples 
and computing miRNA differential expression 
between metastatic and non-metastatic groups in each 
sub-series. Full details on bioinformatics analyses and 
filtering criteria applied for selecting miRNAs for 
validation are provided in Supplementary Methods.  
Confirmation of differentially expressed miRNAs in a 
validation series. Validation of selected miRNAs was 
performed in 49 genetically characterized 
formalin-fixed paraffin-embedded primary tumors. 
Patients provided informed consent for the use of 
specimens and clinical data in accordance with the 
guidelines of the institutional ethics committees. 
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Furthermore, a set of eight paired primary-metastatic 
samples was used to assess miRNAs with significant 
association in the validation step. The main 
characteristics of this series are presented in Table S1. 
RNA extraction and miRNA quantification are 
detailed in Supplementary Methods. One-sided 
nonparametric Mann-Whitney test (GraphPad Prism, 
RRID:SCR_002798) was used to confirm selected 
miRNAs deregulation in validation series, based on 
the assumption that miRNAs had to follow the same 
direction as in the discovery series. 
Clinical outcome analysis of validated miRNAs. Time 
to progression (TTP) was evaluated with the 
Kaplan-Meier method and differences between the 
groups were tested with the log-rank test (SPSS, 
RRID:SCR_002865) for each validated miRNA. TTP 
was defined as the time between the first PPGL 
diagnosis and the first documented metastases. We 
included 246 patients from the discovery and 
validation series, either presenting metachronous 
metastases (presented ≥ one year after diagnosis), or 
with more than one-year follow-up (median 
follow-up time=1290 days). Patients without evidence 
of metastases were censored at the date of the last 
follow-up.  
Risk model of metastasis prediction. The models 
were constructed using stepwise conditional logistic 
regression with the total cohort of 492 patients (443 
from the discovery set plus 49 from the validation 
series). miRNAs associated with a shorter TTP were 
included in the analysis. To combine the data, the 
expression of each miRNA was expressed as a 
dichotomous variable using the median miRNA 
expression as the cutoff in each series. Additionally, 
we included binary variables that identified the 
different series and the SDHB status. The 
classification power of the model was evaluated by 
computing receiver operating characteristic (ROC) 
curves and area under the ROC curves (AUC). 
Integration of miRNA and mRNA expression 
data: Targetome 
Integration of miRNA and mRNA expression profiles 
of the discovery series. To identify genes potentially 
regulated by miR-183-3p and miR-21-3p, we 
considered only samples from the discovery series 
with miRNA and mRNA expression data available 
(n=434), and assumed a regulatory role for a miRNA 
only if the expression level of the miRNA and its 
known mRNA target showed a significant negative 
correlation (P<0.05). Analysis and interpretation were 
carried out in three steps: 
Step 1. Generation of a list of candidate target 
genes for each miRNA from the validated 
miRNA-target interactions (1027 for miR-183-5p and 
853 for miR-21-3p) extracted from miRTarBase release 
6.1 [22] (http://mirtarbase.mbc.nctu.edu.tw/), 
OncomiRDB [23] (http://lifeome.net/database/ 
oncomirdb/) and TarBase v.7.0 [24] 
(http://diana.imis.athena-innovation.gr/DianaTools
/index.php?r=tarbase/index).  
Step 2. Generation of normalized mRNA 
expression matrices including only step 1 genes 
(Targetome) for each sub-series. Further details are 
specified in Supplementary Methods.  
Step 3. Identification of potential target mRNAs 
by matching the expression of the miRNAs and their 
predicted target genes. Spearman’s correlations 
between the six Targetome matrices considering each 
of the three sub-series and the expression of each of 
the two miRNAs were calculated using R. We further 
examined genes with significant correlations (P<0.05) 
and ρ<-0.4 in at least one series. Of these genes, only 
those with either a significant negative correlation in 
both other remaining series or represented by at least 
two probes in one sub-series, were considered. 
Finally, only genes proposed in the literature as 
potential tumor suppressors or involved in 
differentiation were taken into account for further 
consideration in the validation series and the cell 
model. 
Expression of potential target genes in the validation 
series. Candidate target genes selected in the 
integration analysis were quantified by qPCR in the 
49 tumor samples from the validation series as 
described in Supplementary Methods. Spearman’s 
correlation analysis of mRNA-miRNA expression was 
performed. 
Pan-cancer targeted integrative analysis of 
miRNA, mRNA and functional proteomics  
We included 8,960 human cancer samples 
representing 32 different major tumor types for which 
TCGA data on miRNA expression was available. 
RNA-seq, miRNA-seq and reverse-phase protein 
array (RPPA) data were downloaded from UCSC 
Xena (http://xena.ucsc.edu/) and cBioPortal 
(http://www.cbioportal.org/). Spearman’s correla-
tion coefficient was used to assess the correlation of 
miRNA and gene/protein levels (SPSS). Results 
representations were obtained using the ggplot2 R 
package (RRID:SCR_014601).  
PI3K/AKT/mTOR drug sensitivity signature. We 
applied the sensitivity signature scores for the TCGA 
dataset reported by Zhang et al. [25], which were 
derived from the signature obtained in cell lines after 
treatment with PI3K/AKT/mTOR inhibitors [26], and 
performed a correlation analysis between miR-21-3p 
expression and the PI3K/AKT/mTOR drug 
sensitivity signature.  
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Functional assays in cell models 
Plasmids and cell lines. The MIMIC Inducible 
Human Lentiviral microRNA vector with the mCMV 
promoter, the TurboGFP reporter and hsa-miR-183-5p 
(VSH6904-224645044, Dharmacon), and the MIMIC 
Inducible Human Lentiviral microRNA vector with 
the mCMV promoter, the TurboRFP reporter and 
hsa-miR-21-3p (VSH6904-224638696, Dharmacon), were 
stably introduced into the previously generated and 
authentified human neuroblastoma cell lines SK-N-AS 
wild-type (WT) and SK-N-AS SDHB KD (SDHB 
knocked down) [27]. SMARTvector Inducible 
Non-targeting Controls (VSC6570 and VSC6571) were 
used as controls. Transduced cells were selected using 
puromycin at 1 μg/ml, and cells with high expression 
of the reporter were FACS sorted and used for 
subsequent studies.  
Cells were maintained in complete Dulbecco’s 
Modified Eagle Medium (DMEM; Sigma#D5796), 
supplemented with 10% (v/v) fetal bovine serum 
(FBS, Sigma), 1% (v/v) penicillin/streptomycin, 0.6% 
(v/v) Fungizone (Gibco), puromycin (1 μg/ml) and 
G418 (0.3 mg/ml), and maintained at 37°C/5% CO2. 
Cells were routinely tested for mycoplasma and all 
experiments were performed between passage 10 and 
20. miRNA and reporter expression was induced by 
treatment with 1 μg/ml of doxycycline; this 
concentration was selected following optimization 
experiments.  
Wound healing migration assay. Experiments were 
performed as described in Rapizzi et al. [28]. Cell 
migration was quantified using ImageJ software 
(RRID: SCR_003070) at 15h and 24h after scratching, 
based on at least 18 pictures for each time point and 
condition. Experiments were performed in duplicate.  
qPCR. Expression of neuroendocrine-to- 
mesenchymal transition (neuroendoMT) markers and 
potential miRNA gene targets was evaluated in the 
cell model by qPCR (Supplementary Methods).  
Western blotting. Cells were seeded and treated as 
for RNA extraction, and total protein was extracted 
and homogenized in RIPA lysis buffer (Sigma) 
supplemented with protease and phosphatase 
inhibitors (Sigma). Protein concentration was 
measured using the Pierce BCA Protein Assay Kit 
(Thermo Scientific) and total proteins (20 μg) were 
separated by 10% SDS–PAGE and transferred onto a 
polyvinylidene difluoride membrane (Millipore, 
Darmstadt, Germany). Primary antibodies used in 
this study were rabbit anti-Tuberin/TSC2 mAb 
(1:1000; Cell Signaling #4308, RRID: AB_10547134), 
and mouse anti-β-Actin mAb (1:2000; Sigma#A5441, 
RRID: AB_476744). Absolute band intensities of the 
indicated proteins were captured and quantified with 
the Image Lab software v4.1 (BioRad, RRID: 
SCR_014210). β-Actin was used as loading control 
normalizer. Data were expressed in relative units 
using the control condition as reference. 
Drug treatment. Doxycycline-pretreated cells 
(120h) were plated in 96-well plates at a density of 
2000 cells/well and treated with different 
concentrations of rapamycin (Apollo Scientific 
#BIR8101) 24h later. The treatment duration was 
twice the cell doubling time (~96h) and the 
CellTitler-Glo (Promega) cell viability assay was used 
to assess cell viability by luminescence measurement 
using a Victor plate reader (PerkinElmer) 30 min after 
addition of the reagent.  
Detection of circulating miRNAs 
Serum samples from an independent exploratory 
series of 36 PPGL patients were enrolled by the 
COMETE network (France). Authorization was 
obtained from the institutional review board [Comité 
de Protection des Personnes, Ile de France III, June 
2012]. Informed consent for studies on circulating 
miRNAs was signed by all patients. Clinical data from 
this series and the control cohort of adult healthy 
volunteers (n=10) is summarized in Table S2.  
For the preparation of conditioned media (CM), 
wild type and Sdhb-/- immortalized mouse 
chromaffin cells (imCCs) [29] were seeded under 
standard culture conditions (DMEM/Glutamax, 10% 
FBS and 1% penicillin-streptomycin) and maintained 
at 5% CO2/37°C. Once cells reached an optimal 
confluence, the monolayer was washed with 
serum-free (SF) DMEM, and cells were replenished 
with SF media. After 24h, CM was collected, 
centrifuged and cells were counted.  
For miRNA extraction with mirVana™ PARIS™ 
Kit (Thermo Fisher Scientific, Waltham, MA, USA), 
450 µl of serum or filtered CM (0.2 µm pore size) from 
cultured cells were used. Droplet digital PCR was 
utilized for detection and quantification of circulating 
miRNAs as explained in Supplementary Methods. 
One-sided nonparametric Mann-Whitney test 
(GraphPad Prism) was used to test for differences in 
miRNAs levels in circulation between the different 
groups. 
Results 
miRNA profiling uncovers a signature of six 
miRNAs associated with metastatic risk 
Exploring the discovery series, we identified 49 
miRNAs differentially expressed in metastatic 
compared to non-metastatic cases (Figure 1A, Figure 
S2A, Table S3). After an extensive literature review 
(Table S4), six out of the eight selected miRNAs were 
validated (miR-21-3p, miR-182-5p, miR-96-5p, 
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miR-551b-3p, miR-183-5p, miR-202-5p) (Figure S2B, 
Table S3).  
High expression of the five upregulated miRNAs 
was significantly associated with a shorter TTP 
(Figure 1B). Using the paired primary-metastatic 
tissues, we observed that these five miRNAs showed 
similar levels in both tissues, and notably miR-21-3p 
was significantly upregulated in metastases versus 
primary tumors (P=0.0099) (Figure S2B). 
With the validated miRNAs associated with 
shorter TTP, we established a prognostic predictive 
model. The final model, corrected for SDHB status, 
selected miR-21-3p and miR-183-5p as the best 
predictive markers of metastases. The miRNA-based 
classifier (AUC=0.804, 95%CI=0.753-0.855, 
P=4.67·10-18) showed higher accuracy than SDHB 
genotype alone (AUC=0.637, 95%CI=0.563-0.711, 
P=9.29·10-5), while the predictive value increased 
 
 
Figure 1. miRNAs associated with metastatic behavior. (A) Venn diagram of differentially expressed miRNAs (FDR<0.05, |log2 fold change| ≥ 0.75) in the different 
sub-series of the discovery series (n=443). Downregulated miRNAs are indicated with a downward pointing arrow, and upregulated miRNAs are indicated with an upward 
pointing arrow. miRNAs selected for validation are shown in bold and are underlined. (B) Kaplan-Meier plots of time to progression (time between the first PPGL diagnosis and 
the first documented metastases) of patients according to the expression level of the indicated miRNA in tumor tissue. High expression (above the median expression level of 
the whole group) of the miRNA is represented in blue and low expression (below the median level) in green (n=246 patients from the discovery and validation series, either 
presenting metachronous metastases ─ presented ≥ one year after diagnosis ─, or with more than one-year follow-up – median follow-up time=1290 days). Patients without 
evidence of metastases were censored at the date of the last follow-up. P-values were calculated with a log-rank test. N: number of patients. 
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when adding SDHB status to the model (AUC=0.837, 
95%CI=0.787-0.886, P=9.88·10-22) (Figure 2A). When 
segregating patients according to their classifier 
features, 72% of score 3 (high miR-183-5p and 
miR-21-3p levels; SDHB mutated) patients were 
metastatic, compared to the 4.7% of score 0 (low 
miR-183-5p and miR-21-3p expression, and no-SDHB 
mutated) (Figure 2B). Concurrent high expression of 
miR-21-3p and miR-183-5p was significantly more 
associated with shorter TTP than high expression of 
either miRNA alone (Figure 2C).  
 
 
Figure 2. Risk model of metastasis prediction. (A) Receiver operating characteristic curve analysis showing the accuracy of the miR-SDHB classifier to discriminate mPPGL 
patients. Data correspond to all samples from the discovery plus the validation series (n=492). miRNAs associated with a shorter TTP were included in the analysis. To combine 
the data of the different series for the generation of the model, the expression of each miRNA was expressed as a dichotomous variable using the median miRNA expression as 
the cutoff in each series. Binary variables that identified the different series and the SDHB status were included. AUC, 95%CI and P-values are given in the text. (B) Schematic 
representation of patients from discovery and validation series (n=492) divided into four groups depending on the miR-SDHB classifier (score 3 = high miR-183-5p and high 
miR-21-3p and SDHB mutated; score 2 = high miR-21-3p or high miR-183-5p and SDHB mutated, or high miR-21-3p and miR-183-5p and SDHB not mutated; score 1 = high 
miR-21-3p or high miR-183-5p or SDHB mutated; score 0 = none of the aforementioned criteria apply). Red icons: patients with mPPGL; green icons: non-metastatic patients. (C) 
Kaplan-Meier plot of TTP of patients according to the expression levels of the miRNAs indicated. High and low expression indicates expression above and below the median 
expression level of the whole group, respectively. N: number of patients. P-values were calculated with a log-rank test. (D) Wound healing assay in SK-N-AS cells with/without 
SDHB stably silenced and with/without ectopic expression of miR-21-3p and miR-183-5p. Wound area was assessed at 0, 15 and 24 h. Quantification is based on 18 
pictures/condition, n=2. Error bars represent SD.*P<0.05, **P<0.01; two-tailed unpaired t-test. Scale bars=100 µm. (E, F) Expression of the indicated mesenchymal and 
neuroendocrine genes observed in the SK-N-AS cell model and in the discovery series. (E) Log2 fold change expression of the indicated genes relative to WT 
TurboRFP-TurboGFP-expressing control cells after normalization of each sample to β-actin. All cells were pretreated with doxycycline (1µg/ml, 120h). Expression is reported as 
mean of triplicates and error bars represent SD. (F) Spearman's correlations (rho) between the genes shown in Figure (E) and miR-21-3p (smooth columns) or miR-183-5p 
(dotted columns) expression in the discovery series. Bars indicate the mean of the 3 sub-series; individual values of each sub-series are also shown (•=sub-series 1, ■=sub-series 
2, ▲=sub-series 3). ***P<1·10-9, **P<1·10-4, *P<0.05. DOX+: doxycycline pretreated cells (1µg/ml, 120h). WT: wild type; OX: overexpressing; KD: knock down. 
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High miR-183-5p and miR-21-3p expression 
trigger features related to a pro-metastatic 
phenotype  
To further explore the role of miR-183-5p and 
miR-21-3p in metastasis, we evaluated in a cell model 
migration, proliferation and transition to a 
mesenchymal state, characteristics classically 
associated with an aggressive phenotype. 
SDHB-deficient cells have an increased 
migration capacity compared to WT cells [29]. We 
replicated this phenotype in a wound healing assay 
and also observed increased migration of cells 
overexpressing miR-183-5p and miR-21-3p, both in 
the presence and absence of a functional SDHB gene 
(Figure 2D). However, we did not observe differences 
in cell proliferation.  
It has been reported that SDHB loss is associated 
with a neuroendoMT [30], and we therefore assessed 
the expression of neuroendocrine (SYP, ENO2, 
INSM1) and mesenchymal (CDH2, FOXC2, SNAI2, 
SNAI1) markers to study whether overexpression of 
miR-21-3p and miR-183-5p acerbated this feature. 
Although cells did not show obvious morphological 
changes, overexpression of miR-21-3p and 
miR-183-5p increased expression of mesenchymal 
markers and decreased expression of neuroendocrine 
ones, both in WT and in SDHB-silenced cells (Figure 
2E).  
Expression of the same markers was evaluated in 
the discovery series. We observed that mesenchymal 
markers showed a positive correlation and 
neuroendocrine markers a negative one with the 
expression of the two miRNAs (Figure 2F). miR-21-3p 
generally increased the expression of mesenchymal 
markers, whereas miR-183-5p decreased the 
expression of neuroendocrine genes. 
Integration of mRNA and miRNA expression 
reveals that TSC2 mRNA is reduced upon high 
miR-21-3p levels  
We integrated the miR-21-3p and miR-183-5p 
expression data with their targetomes to identify 
potential relevant targets for these miRNAs. A 
significant negative correlation was observed in 43.3% 
of predicted miR-21-3p targets, and in 10.7% of 
miR-183-5p ones in at least one sub-series (Figure 3A 
and 3B); of these, only ten genes met the established 
filtering criteria for miR-21-3p and four for 
miR-183-5p (Table S5 and S6). After applying 
biological criteria (Table S7), six genes (TSC2, SGPL1, 
CREBL2 and CALM1 for miR-21-3p; SMAD7 and RAI2 
for miR-183-5p) were selected for replication in the 
validation series (Figure 3C). Only TSC2 expression 
showed a significant negative correlation with miR- 
21-3p expression in this series (ρ=-0.324, P=0.023).  
In parallel, 32 cancers TCGA data sets were used 
to assess the correlation between the expression of 
selected gene-miRNA pairs. Of them, 62.5% showed a 
significant negative correlation between miR-21-3p 
and TSC2 expression. Furthermore, the analysis 
performed with the whole PanCan (n=8,960 tumors) 
cohort indicated that only TSC2 and CREBL2 showed 
a significant negative correlation (ρ<-0.3, P<1·10-200) 
with miR-21-3p expression (Figure 3D).  
Expression of the six aforementioned genes was 
evaluated in the cell models overexpressing the 
miRNAs, and only TSC2 showed a significant 
decrease in expression (Figure 3E). 
Using TargetScan (http://www.targetscan.org/ 
vert_72/), we found binding sites at 3’UTR in 
CREBL2, SGPL1 and CALM1 (Figure S3A, S3B and 
S3C) for miR-21-3p, but none in the remaining genes. 
However, extensive visual inspection of miRNA 
sequences and the 3’UTRs of TSC2, SMAD7 and RAI2 
revealed potential binding sites (Figure S3A, S3E and 
S3F).  
Role of miR-21-3p in mTOR pathway 
regulation 
Using functional proteomics data from the 
TCGA project, we evaluated the effect that miR-21-3p 
could have on protein levels. In PPGLs, we found a 
significant negative correlation for miR-21-3p 
expression with TSC2 protein levels (ρ=-0.31, 
P=4.5·10-3), as well as a positive one with pS6 (in 
Ser235/236: ρ=0.36, P=9.1·10-4; in Ser240/244: ρ=0.20, 
P=0.07) (Figure 4A); a positive correlation tendency 
with pAKT levels was also observed (Figure S4).  
We also explored the potential role of miR-21-3p 
in other cancer types with high levels of mTOR 
activity [25]. Apart from PPGL, low-grade glioma 
(LGG) also exhibits a significant negative correlation 
between miR-21-3p and TSC2 (ρ=-0.18, P=1.3·10-4), as 
well as a positive one with pS6 levels (in Ser235/236: 
ρ=0.27, P=1.7·10-8; in Ser240/244: ρ=0.23, P=6.6·10-7) 
(Figure 4A). By contrast, in cancer types with the 
lowest levels of mTOR activity (kidney chromophobe 
–KICH– and pancreatic adenocarcinoma –PAAD–) no 
significant correlations were observed. 
Downregulation of TSC2 in cells overexpressing 
miR-21-3p was further demonstrated by Western blot 
(Figure 4B). 
To determine whether miR-21-3p levels could 
also be associated with an increased response to drugs 
targeting mTOR pathway, we explored the 
inhibitor-sensitivity mRNA signature proposed by 
Zhang et al. [25] for TCGA project samples. This 
signature score correlated significantly with 
miR-21-3p levels in PPGL and LGG (Figure 4C), but 
not for KICH and PAAD (Figure S5).  
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Figure 3. Identification of potential gene targets of miR-21-3p and miR-183-5p. (A, B) Venn diagrams summarizing significant genes showing a negative correlation 
(P<0.05) with miR-21-3p and miR-183-5p expression, respectively, in each sub-series of the Discovery series. Only genes shared between at least two sub-series are shown; rho 
and p-values are shown in Tables S4 and S5. Genes selected for validation are shown in bold. (C) Bubble diagram showing the correlation between mRNA levels of selected target 
genes in the discovery and validation series; the colors of the bubbles indicate the rho-value and their diameter is proportional to – log10(P) as indicated below the panel. NA: data 
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not available. (D) Bubble diagrams showing the correlations between mRNA expression of the selected target genes and miRNA expression across 32 TCGA projects 
representing the major cancer types: LAML, acute myeloid leukemia; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; LGG, brain lower grade glioma; 
BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; 
READ, rectum adenocarcinoma; ESCA, esophageal carcinoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell 
carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; DLBC, lymphoid 
neoplasm diffuse large B-cell lymphoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and 
paraganglioma (‘PPGL’ in our report); PRAD, prostate adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular 
germ cell tumors; THYM, thymoma; THCA, thyroid carcinoma; UCS, uterine carcinosarcoma; UCEC, uterine corpus endometrial carcinoma; PANCAN: dataset downloaded 
from UCSC Xena. Glioblastoma multiforme was not included in the study since miRNA expression data was not available in UCSC Xena. n: number of samples per project. 
Colors and diameters of the bubbles are as in (C) and are summarized at the bottom of the panel. (E) Normalized mRNA expression of genes selected from the targetome in 
miR-21-3p─TurboRFP expressing cells (TSC2, SGPL1, CREBL1, CALM1) or miR-183- 5p─TurboGFP expressing cells (SMAD7). Expression for each condition is normalized to 
β-actin and expression in control cells (mean + SD; n=3). We represent the average of WT and SDHB KD cells of the mean-centered expression of the miRNA expressing cells 
(DOX+) over TurboRFP or TurboGFP expressing control cells (DOX+), respectively after initial doxycycline stimulation (1µg/ml) at t0. Two-tailed unpaired t-test was applied 
to test for differences with control cells not overexpressing miRNA (*: P<0.05). Red arrows indicate medium changes (DOX-stimulation). 
 
Figure 4. Involvement of miR-21-3p in mTOR pathway regulation. (A) Bubble plot indicating Spearman's correlations (rho) between key mTOR pathway proteins that 
could be affected by TSC2 mRNA downregulation and miR-21- 3p upregulation. TCGA RPPA data of TSC2 protein, p-S6 S235/236 and S240/244 was correlated with miR-21-3p 
expression in PPGL and LGG TCGA samples (showing the highest mTOR pathway activity reported by Zhang et al.[25]), as well as in KICH and PAAD samples (lowest levels of 
mTOR pathway activity); bubble colors indicate the rho coefficient and their diameter is proportional to – log10(P) as indicated below the panel. (B) Representative western blot 
of TSC2 expression in SK-N-AS WT and SDHB KD cells, with or without ectopic expression of miR-21-3p (miR-21-3p-TurboRFP expressing cells DOX + and control TurboRFP 
expressing cells DOX +, respectively). Relative quantification of the TSC2 signal in miR-21-3p expressing cells was normalized to the one in TurboRFP expressing cells (DOX +). 
B-actin has been used as loading control. (C) Scatter plots showing the correlation between miR-21-3p expression and PI3K/AKT/mTOR drug sensitivity signature (from Zhang 
et al.[25]) in PPGL (n=178) and LGG (n=514) tumors from the TCGA project. Spearman's correlation coefficient (ρ) and P-values are shown. (D) Cell viability percentage in 
SK-N-AS miR-21-3p – TurboRFP cells (induced with doxycycline [DOX+] or not [DOX-]) and in SK-N-AS TurboRFP [DOX+] cells treated with the indicated concentrations 
of rapamycin for 96h. Proportion of viability is shown as the mean ± SD of 2-paired independent experiments performed in triplicate. Two-tailed unpaired t-test was applied to 
test for differences (*: P<0.01). DOX+: doxycycline pretreated cells (1µg/ml, 120h). 
 
Furthermore, cells with ectopic expression of 
miR-21-3p showed a significant reduction in cell 
proliferation after rapamycin treatment in comparison 
to their controls (Figure 4D).  
Metastatic miRNA signature is detected in the 
circulation 
We explored whether the miRNA signature 
displayed by metastatic tumors could be detected in 
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circulation of an independent series of PPGL patients. 
We observed that serum levels of all miRNAs of the 
signature except miR-202-5p were significantly higher 
in PPGL patients than in healthy controls, regardless 
of the metastatic status (Figure 5). miR-96-5p, 
miR-182-5p and miR-21-3p remained elevated in 
PPGL vs. healthy individuals, with miR-21-3p being 
the best discriminator (AUC=0.96; P=0.0001). Notably, 
circulating levels of all miRNAs of the signature 
(except miR-551b-3p and miR-202-5p) exhibited a 
tendency towards increased expression in mPPGLs 
compared to non-metastatic cases, reaching statistical 
significance in the mPPGL subgroup with evidence of 
progressive disease (Table S8). Levels of miR-183-5p 
remained significantly higher in patients with 
progressive vs. stable mPPGL. Levels of miR-21-3p 
were significantly correlated with metastatic burden 
(r=0.38; P=0.04).  
To better ascertain if miRNAs of the metastatic 
signature are secreted by chromaffin cells, we 
quantified levels of these miRNAs in conditioned 
medium of imCCs, a model of PPGL. Consistent with 
the findings in serum of PPGL patients, miR-202-5p 
and miR-551b-3p, which exhibited low levels in 
patients, were undetectable in imCCs, whereas the 
levels of all other miRNAs were higher in Sdhb-/- 
compared to WT cells (Figure S6).  
Discussion  
Precision cancer medicine focuses on patients’ 
stratification according to their metastatic risk, and/or 
potential treatment benefits. Rare cancers are 
becoming models for personalized medicine as more 
clinical, genetic and genomic knowledge leads to 
insights into signaling pathways and mechanisms 
underlying their pathogenesis. Here, we propose a 
new metastatic risk miRNA signature, with 
prognostic value and related to shorter TTP. 
Eventually, this signature could be measured as a 
circulating biomarker in serum from PPGL patients. 
Furthermore, our study reveals a new putative 
miR-21-3p/TSC2/mTOR regulatory axis as a 
potential treatment target. 
The high expression cluster miR-183/96/182-5p 
in mPPGL was already reported in SDHx-related 
PPGLs [16, 17], but we now identified its high 
expression in mPPGLs regardless of their genotype. 
We also uncovered three novel markers of mPPGL, 
which have been described to be deregulated in 
multiple cancers (see Table S4). The fact that the 
model only includes miR-21-3p and miR-183-5p, and 
is able to discriminate metastatic patients with higher 
accuracy than SDHB-positive status (widely accepted 
as a mPPGL marker), suggests that additional 
important molecular features are involved in PPGL 
progression. This hypothesis is supported by the 
enhanced collective cell migration, likely driven by a 
neuroendoMT phenotype, observed in the wound 
healing assay after overexpression of miR-21-3p and 
miR-183-5p in an SDHB-silenced cell line.  
 
 
Figure 5. Detection of mPPGL-related miRNAs in the circulation. Box and whisker plots indicate serum levels of the indicated miRNAs in healthy (H, yellow), 
non-metastatic (B, green) and mPPGL patients (Ms and Mp; orange and brown, respectively) determined by ddPCR. Distinction between stable mPPGL (Ms) and progressive 
mPPGL (Mp) was based on clinical and radiological data (see Table S8). Mann-Whitney test was applied to test for significant differences. Significant differences between H and 
the patient cohort (including B, Ms and Mp) are indicated with yellow asterisks, between H and B with green asterisks, between B and metastatic (including Ms and Mp) patients 
with pink asterisks, between B and Mp with blue asterisks, and Ms and Mp with red asterisks. *: P<0.05, **: P<0.01 and ***: P<0.00001. 
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The integration of miR-21-3p and miR-183-5p 
with mRNA data identified targets potentially 
regulated by those miRNAs, and that miR-21-3p may 
be involved in the regulation of the mTOR pathway 
through TSC2 mRNA downregulation. In this regard, 
the 3’ UTR of TSC2 contains a 6mer pairing with 
miR-21-3p with a single nucleotide mismatch, which 
is compensated by a 4nt compensatory site 
downstream of the miRNA pairing sequence, similar 
to previously reported cases [31]. In addition, 
although other mechanisms such as targeting the 
5’UTR and the open reading frame could also be 
considered, we cannot exclude the possibility of 
indirect effects of other responsive UTR targets of 
miR-21-3p as 43.3% of the 852 potential miR-21-3p 
gene targets showed an inverse correlation with the 
miRNA levels. In fact, we also found a weaker 
positive correlation of miR-21-3p with pAKT levels in 
PPGL and LGG, indicating a possible regulation 
upstream of the pathway through AKT 
phosphorylation, TSC1-TSC2 complex destabilization, 
TSC2 ubiquitination and, consequently, mTOR 
pathway activation [32].  
To note, constitutive activation of 
PI3K/AKT/mTOR signaling is a feature described in 
PPGLs and associated with increased activation of 
pAKT [33]. Actually, both PPGL and LGG exhibit 
activation of this pathway despite a lack of canonical 
somatic alterations [25]. Taking advantage of the 
phospho-proteomics data from the TCGA project, we 
have shown that miR-21-3p correlates significantly 
with markers of mTOR pathway activation. We did 
not observe the effects on mTOR pathway activation 
after miR-21-3p overexpression in the cell model. 
However, protein output can vary by 2-fold without 
detectable effects, and consequences of most of the 
miRNAs alone are challenging to detect in the lab [31]. 
Taking into account our findings, additional 
mechanisms of activation of the mTOR pathway, such 
as miR-21-3p regulation, should be considered.  
Studies targeting mTOR in preclinical PPGL 
models have provided some promising results 
[34–38], and there is also immunohistochemical 
evidence of heterogeneous mTOR activation in 
mPPGLs [39–41]. Nevertheless, discordant results 
have been reported in clinical studies with everolimus 
[42–44] that could be due to the absence of 
appropriate inclusion criteria using molecular 
markers. In fact, few studies have examined markers 
for stratifying mPPGL patients for targeted molecular 
therapies [3]. With this in mind, we have found in 
PPGL and LGG that miR-21-3p shows a significant 
correlation with a sensitivity signature of drugs 
targeting mTOR pathway. The enhanced sensitivity to 
rapamycin of our miR-21-3p overexpressing cell 
model indicates that, indeed, miR-21-3p could be a 
potential marker for selecting candidate patients for 
treatment with mTOR inhibitors.  
Our findings support the concept of a miRNA 
signature for patient stratification according to 
metastatic risk. Importantly, a significant fraction of 
the metastatic miRNA signature was detected in the 
serum of an independent cohort of patients showing 
increased levels of these miRNAs. miRNAs associated 
with a shorter TTP in tumor tissue (miR-21-3p, 
miR-183-5p, miR-182-5p and miR-96-5p) were also 
increased in the serum of metastatic cases and showed 
the highest levels during the progressive phase of 
metastasis. The mechanisms of how these 
metastasis-related miRNAs enter the circulation and 
whether they are biologically functional warrant 
further investigation. We show that circulating 
miRNAs are indeed secreted by imCCs, and that this 
secretion is increased in cells with a more aggressive 
phenotype [30]. While these miRNAs may have 
cell-intrinsic roles, as we showed for miR-21-3p, it is 
also possible that they participate in cell-cell 
communication by controlling the tumor 
microenvironment. Regulation of gene expression by 
miRNAs outside the cell of origin may also account 
for cancer progression and therapy resistance [45]. 
These findings extend the potential clinical utility of 
detecting the metastatic miRNA signature in liquid 
biopsies, but further prospective studies will be 
required to address this issue.  
In conclusion, the power of a large sample series 
combined with multi-omic integration and the 
accessibility of TCGA data of other cancer entities has 
enabled the identification of robust biomarkers 
relevant to disease progression. This strategy is also a 
powerful tool for elucidating appropriate therapeutic 
options based on molecular biomarkers in PPGL, 
which is a significant step towards achieving 
precision medicine for patients with mPPGL – a 
disease with no FDA-approved therapies [2].  
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